HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.
May 01, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterates a Buy rating on Foghorn Therapeutics with a $20 price target.
The reiteration of a Buy rating and a maintained price target of $20 by a reputable analyst like Andrew Fein suggests a strong vote of confidence in Foghorn Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in FHTX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100